A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

As a result, you may be surprised by the changes in symptoms and treatment possibilities available to you once you’re diagnosed with SPMS. Keep reading to learn what to expect if you were recently ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory small molecule therapy that can cross the blood-brain barrier may be attractive ...

Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...